A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D
However, Wegovy (the same semaglutide molecule at weight-loss doses) is FDA-approved for chronic weight management
Treatment continuation is generally recommended when: Vomiting is mild and intermittent rather than severe and persistent Symptoms are improving over time with supportive measures You are achieving good glycaemic control and other therapeutic benefits Dietary modifications and appropriate symptom management provide adequate relief You are able to maintain adequate hydration and nutrition In clinical practice, many patients who experience initial vomiting find that symptoms resolve within 4-8 weeks as tolerance develops
When restarting after an extended break, beginning again at a lower dose is generally recommended to reduce the risk of gastrointestinal adverse effects, even if you previously tolerated higher doses well
View our Privacy Policy Copyright 2026 Bettormetrics To learn more about Bettormetrics and how it can improve your trading performance, email [email protected] Bettormetrics is a trading name of Open Metrics Limited, registered in England and Wales under company number 13785217 and with its registered office at: 2 Toomers Wharf, Canal Walk, Newbury, Berkshire, RG14 1DY